Julia Feige, Christiana Schernthaner, Peter Wipfler, Johann Sellner
Multiple sclerosis and related disorders 2020 FebFingolimod is a sphingosine-1-phosphate 1 (S1P1) modulator which retains lymphocytes in secondary lymphoid organs and is approved for the treatment of relapsing multiple sclerosis (MS). The decrease of heart rate and AV block are reversible side-effects of treatment initiation. We report a case of persistent high-grade atrioventricular (AV) block 450 days after start of fingolimod and permanent pacemaker requirement in late-onset relapsing multiple sclerosis (MS). We discuss emerging risk factors for cardiac conduction deficits including the recently discovered vagomimetic effects of S1P1 modulation, structural brain and spinal cord damage, ageing and comorbidities. Copyright © 2019 Elsevier B.V. All rights reserved.
Julia Feige, Christiana Schernthaner, Peter Wipfler, Johann Sellner. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod. Multiple sclerosis and related disorders. 2020 Feb;38:101515
PMID: 31751857
View Full Text